Skip to main content

Table 2 Treatment modalities and outcomes of women with radiogenic angiosarcoma of the breast

From: Radiogenic angiosarcoma of the breast: case report and systematic review of the literature

Author

Year

Treatment modalities (Initial)

Treatment modalities (Recurrence)

Chemotherapy (n)/ regimen

RXT (n)/ gray

Recurrence-Free survival (m)

Overall survival (m)

Fodor [4]

2006

MAS (8)

S + CHXT (1)

1/DOCE

–

16

26

Marchal [5]

1999

MAS (4);MAS + CHXT (2); MAS + RXT (2);MAS + S (1)

S (1);RXT; CHXT (7)

2/−

3/30;45a

7

15

D’Angelo [6]

2013

MAS (65);S (13)a; CHXT (9)

CHXT (23)

23/DOX (9), PAC (3), SORA (3), BRIV (2), IFO (1), DOX + PAC (1), GEM+DOCE (1), SIR (1)

–

16

36

Strobbe [9]

1998

MAS (20);MAS + S (1)

S (7)

–

–

13

27

Smith [12]

2014

MAS (6);MAS + RXT (8)

RXT (6)

–

14/45 (2);60 (3);75 (9)

 

97

West [19]

2005

MAS (2);MAS + RXT (1);MAS + CHXT (1)

S (1); CHXT (1)

2/TAX;ADR

2/−

26;6;3;5

26;19;12;6

Rao [20]

2003

MAS (3)

S + CHXT (1)

–

–

41;3;7

41;12;7

Polgár [21]

2001

MAS (1);NT (1)

MAS (1)

–

–

36;4

36;4

Vesoulis [22]

2000

MAS + CHXT (1)

 

1/−

–

–

–

Wijnmaalen [24]

1993

MAS (2);MAS + S (1)

S (1)

–

–

7;16;30

7;30;34

Otis [27]

1986

S (2)

–

1/−

–

2

–

Armengot-Carbó [29]

2012

MAS (1)

–

–

–

9

9

Fernández [30]

2006

MAS (2)

S (1)

–

–

8;50

10;50

Colville [33]

2000

S (1)

MAS;S;RXT (1)

–

1/40

8

20

Hogewind [34]

2004

MAS (2)

S (1)

–

–

4;24

4,24

Williams [35]

2004

MAS (1)

–

–

–

5

5

Deutsch [37]

2003

MAS + S (1)

S;RXT (1)

–

1/−

4

23

Hildebrandt [41]

2001

MAS (1)

S (1)

–

–

16

23

Esler-Brauer [7]

2007

MAS (1)

–

–

–

45

45

Catena [42]

2006

MAS (1)

–

–

–

10

10

Moe [43]

2007

MAS (1)

S;CHXT (1)

1/DOX;IFO

–

2

20

Hodgson [45]

2007

MAS (25)

 

–

–

–

–

Soldić [48]

2009

MAS

–

–

–

16

16

Zucali [53]

1994

S (1);MAS (2); MAS + S (1)

S + RXT (1);CHXT (1)

1/−

1/60

96;4;13

96;7;24

Aydogdu [54]

1996

MAS (1)

–

–

–

3

–

Weber [56]

1995

S (2);RXT + CHXT (1)

RXT;CHXT (1)

1/5-FU, DOX

–

36;24

36;24

Majeski [57]

2000

MAS + S (1)

S (1)

–

–

26

29

Nakamura [60]

2007

MAS + CHXT (1)

–

1/PAC

–

15

15

Billings [64]

2004

MAS (10); S (10)a

CHXT (4)

4/−

–

–

42

Navarro Cecilia [67]

2015

MAS (1)

S (1)

–

–

1

7

Uryvaev [68]

2015

MAS (3);MAS + RXT (3)

RXT (2);CHXT (3)

3/ADR + IFO (1); DOX + PAC (2)

3/50 (2);16 (1)

–

43

Gennaro [69]

2010

MAS (9)

–

5/ADR + IFO

–

–

–

Feigenberg [8]

2002

MAS (3)

RXT (3)

–

3/60 (2);50 (1)

2;1;22

41;60;22

Hui [71]

2012

MAS (1);MAS + RXT (4);MAS + CHXT (3)

–

3/PAC

–

–

–

Adhikari [72]

2002

S + RXT + CHXT (1)

S (1)

1/ADR + CYC

1/50

13

16

Hanasono [74]

2005

S (1)

S,CHXT (1)

–

–

2

13

Mocerino [75]

2016

MAS (1)

S;CHXT;RXT (1)

1/BLEO;DOX

1/60

12

24

Moskaluk [78]

1992

S (1)

MAS (1)

–

–

24

96

Pooled Analysis

–

MAS (83%); S (13%); CHXT (4%) (adjuvant); RXT (6%) (adjuvant)

CHXT (58%); S (33%); RXT (30%)b

–

–

15.9

27.4

  1. Abbreviations: 5-FU 5-fluorouracil, ADR adriamycin, BLEO bleomycin, BRIV brivanib, CHXT chemotherapy, CYC cyclophosphamide, DOCE docetaxel, DOX doxoribicin, GEM gemcitabine, IFO ifosfamide, m months, MAID doxorubicin, ifosfamide, dacarbazine, MAS mastectomy, n number, NT no treatment, PAC paclitaxel, RXT radiotherapy, S surgery, SIR sirolimus, SORA sorafenib
  2. aMissing cases not documented
  3. bmultiple therapies possible